NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.
NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.
复制标题
DOI:
10.1016/j.ccr.2010.04.023
复制
发表时间:
2010-06-15
期刊:
影响因子:
50.3
通讯作者:
Zhang XK
中科院分区:
文献类型:
--
作者:
Zhou H;Liu W;Su Y;Wei Z;Liu J;Kolluri SK;Wu H;Cao Y;Chen J;Wu Y;Yan T;Cao X;Gao W;Molotkov A;Jiang F;Li WG;Lin B;Zhang HP;Yu J;Luo SP;Zeng JZ;Duester G;Huang PQ;Zhang XK
Non-steroidal anti-inflammatory drugs (NSAIDs) exert their anti-cancer effects through cyclooxygenase-2 (COX-2)-dependent and -independent mechanisms. Here we report that Sulindac, an NSAID, induces apoptosis by binding to retinoid X receptor-α (RXRα). We identified an N-terminally-truncated RXRα (tRXRα) in several cancer cell lines and primary tumors, which interacted with the p85α subunit of phosphatidylinositol-3-OH kinase (PI3K). Tumor necrosis factor-α (TNFα) promoted tRXRα interaction with the p85α, activating PI3K/AKT signaling. When combined with TNFα, Sulindac inhibited TNFα-induced tRXRα/p85α interaction, leading to activation of the death receptor-mediated apoptotic pathway. We designed and synthesized a Sulindac analog K-80003, which has increased affinity to RXRα but lacks COX inhibitory activity. K-80003 displayed enhanced efficacy in inhibiting tRXRα-dependent AKT activation and tRXRα tumor growth in animals.
登录
查看更多内容
影响因子:
64.8
作者:
Kurumbail, RG;Stevens, AM;Stallings, WC
通讯作者:
Stallings, WC
影响因子:
16
作者:
Bourguet, W;Vivat, V;Moras, D
通讯作者:
Moras, D
影响因子:
50.3
作者:
Kolluri SK;Zhu X;Zhou X;Lin B;Chen Y;Sun K;Tian X;Town J;Cao X;Lin F;Zhai D;Kitada S;Luciano F;O'Donnell E;Cao Y;He F;Lin J;Reed JC;Satterthwait AC;Zhang XK
通讯作者:
Zhang XK
影响因子:
56.9
作者:
Li, H;Kolluri, SK;Zhang, XK
通讯作者:
Zhang, XK
影响因子:
64.8
作者:
Irmler, M;Thome, M;Tschopp, J
通讯作者:
Tschopp, J